Search Results 181-190 of 16388 for infliximab

  1. A Study Of Efficacy And Safety Of Mongersen (GED-0301) For The Treatment Of Adult And Adolescent Subjects With Active Crohn's Disease - Mayo Clinic

    ... infliximab, adalimumab, certolizumab, or vedolizumab). Exclusion Criteria: • The presence of any of the following will exclude a subject from enrollment ...

  2. Publications - C. Scott Collins, M.D. - Mayo Clinic

    ... infliximab. BMJ Case Rep. 2013 Mar 15; 2013. View PubMed; Feely MA, Collins CS, Daniels PR, Kebede EB, Jatoi A, Mauck KF. Preoperative testing before ...

  3. Sarilumab (subcutaneous route) - Side effects & dosage - Mayo Clinic

    Baricitinib; Cariprazine; Cholera Vaccine, Live; Dengue Tetravalent Vaccine, Live; Infliximab; Influenza Virus Vaccine, Live; Lumateperone; Measles Virus ...

  4. A Study to Evaluate the Safety and Effectiveness of Adult Allogeneic Expanded Adipose-derived Stem Cells (eASC) for the Treatment of Complex Perianal Fistula(s) in Patients with Crohn's Disease - Mayo Clinic

    Infliximab: at least 14 weeks treatment at the approved doses for induction and/or maintenance in Crohn´s disease prior to screening for the study. For ...

  5. Ustekinumab-hmny (intravenous route, subcutaneous route) - Side effects & dosage - Mayo Clinic

    Infliximab; Influenza Virus Vaccine, Live; Measles Virus Vaccine, Live; Mumps Virus Vaccine, Live; Poliovirus Vaccine, Live; Rotavirus Vaccine, Live; Rubella ...

  6. Brodalumab (subcutaneous route) - Side effects & dosage - Mayo Clinic

    Finerenone; Haloperidol; Infliximab; Influenza Virus Vaccine, Live; Lemborexant; Loperamide; Measles Virus Vaccine, Live; Methylergonovine; Mifepristone; Mumps ...

  7. Natalizumab-sztn (intravenous route) - Side effects & uses - Mayo Clinic

    Infliximab; Vedolizumab. Other Interactions. Certain medicines should not be used at or around the time of eating food or eating certain types of food since ...

  8. Certolizumab (subcutaneous route) - Side effects & dosage - Mayo Clinic

    Infliximab; Influenza Virus Vaccine, Live; Measles Virus Vaccine, Live; Mumps Virus Vaccine, Live; Natalizumab; Poliovirus Vaccine, Live; Rituximab; Rotavirus ...

  9. A Study To Assess The Effectiveness And Safety Of Pacritinib In Patients With VEXAS Syndrome (PAXIS) - Mayo Clinic

    Anti-TNFα agents except for etanercept (e.g., infliximab): 60 days; Canakinumab: 60 days; Intravenous anti-IL-6 agents: 42 days; Subcutaneous anti-IL-6 agents ...

  10. A Study To Evaluate The Accuracy Of The Length-109 Probe Set Panel (A Genetic Test) In Predicting Response To Golimumab In Participants With Moderately To Severely Active Ulcerative Colitis - Mayo Clinic

    Participation eligibility · biologic therapy targeted at tumor necrosis factor alpha (eg, infliximab, adalimumab, golimumab, etanercept, certolizumab); ...